In the AACG in-office treatment protocol, which regimen is prescribed first?

In the AACG in-office treatment protocol, which regimen is prescribed first?

• A. Three topical drops at 15-minute intervals: Apraclonidine 0.5%, Timolol 0.5%, Dorzolamide 2%
• B. Oral acetazolamide 250 mg
• C. Prednisone 40 mg daily
• D. Pilocarpine eye drops every hour

Answer: (A)

In acute angle-closure glaucoma, the priority is to lower intraocular pressure quickly to prevent optic nerve damage, using multiple topical medications that cut aqueous humor production from different angles. The fastest, safest in-office approach is to give three topical drops in quick succession, each about 15 minutes apart, to achieve a rapid, additive drop in production. Apraclonidine 0.5% reduces aqueous production (with a bit of outflow effect), timolol 0.5% is a strong beta-blocker that substantially lowers production, and dorzolamide 2% (a carbonic anhydrase inhibitor) provides another independent mechanism to reduce production. This combination works together to lower IOP rapidly while you monitor the patient for any systemic or local side effects. Oral acetazolamide can be added if needed, especially if IOP remains high after the topical drops, but it isn’t the first in-office regimen. Prednisone doesn’t address the immediate pressure issue. Pilocarpine is often avoided initially in this setting because severe IOP can cause iris ischemia and pilocarpine may not help—and can sometimes worsen pupil block until the IOP starts to fall.

In acute angle-closure glaucoma, the priority is to lower intraocular pressure quickly to prevent optic nerve damage, using multiple topical medications that cut aqueous humor production from different angles. The fastest, safest in-office approach is to give three topical drops in quick succession, each about 15 minutes apart, to achieve a rapid, additive drop in production. Apraclonidine 0.5% reduces aqueous production (with a bit of outflow effect), timolol 0.5% is a strong beta-blocker that substantially lowers production, and dorzolamide 2% (a carbonic anhydrase inhibitor) provides another independent mechanism to reduce production. This combination works together to lower IOP rapidly while you monitor the patient for any systemic or local side effects.

Oral acetazolamide can be added if needed, especially if IOP remains high after the topical drops, but it isn’t the first in-office regimen. Prednisone doesn’t address the immediate pressure issue. Pilocarpine is often avoided initially in this setting because severe IOP can cause iris ischemia and pilocarpine may not help—and can sometimes worsen pupil block until the IOP starts to fall.